The U.S. Senate Finance Committee and the House Oversight Committee started hearings focused on high drug prices.
Evidenced by the move to measure and reimburse providers based on the quality, as opposed to the quantity, of care delivered, the healthcare industry is shifting from a fee-for-service to an outcomes or value-based model.
Biogen Inc. beat analysts’ estimates for fourth-quarter profit and revenue, buoyed by higher sales of the company’s top-selling multiple sclerosis drugs, and forecast full-year profit ahead of Wall Street expectations.
CVS Health Corp. – a top U.S. manager of pharmacy benefits – added new migraine drugs from Teva Pharmaceutical Industries Ltd. and Eli Lilly and Co. to the PBM’s list of covered drugs, excluding a rival treatment from Amgen Inc.
As the United Kingdom nears closer to exiting the European Union without a deal, drug manufacturers such as Novartis are preparing contingencies for how they will continue to provide medications – many of them life-saving – for patients in the U.K.
Additional shortages of blood pressure drugs in the United States are possible following recent recalls related to traces of a probable carcinogen found in some versions a particular class of hypertension medicines, the U.S. Food and Drug Administration said.
A new not-for-profit supplier of generic drugs formed by a consortium of hospitals systems expects to be able to provide about 20 products during 2019 to alleviate shortages of medicines used during surgeries and to treat life-threatening conditions, such as septic shock.
Amgen announced that the European Commission approved an expanded indication for Blincyto monotherapy to include adult patients with Philadelphia chromosome negative CD19 positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease greater than or equal to 0.1 percent.
The cost of insulin for treating type 1 diabetes in the United States nearly doubled over a five-year period, underscoring a national outcry over rising drug prices, according to a new analysis shared with Reuters.
AbbVie Inc.’s blockbuster cancer treatment Imbruvica in combination with chemotherapy agents failed to meet the main goal in a late-stage study of patients with a form of pancreatic cancer.